Clinical Trial Update: A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1, first‑in‑human study of escalating oral doses of TVB-2640 in patients with solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• TVB-2640

Snippet

Sponsor: Sagimet Biosciences Inc. | Conditions: Solid Malignant Tumor | Phase 1 | Status: COMPLETED